

Please amend the specification as follows.

**Page 18, Paragraph at lines 15+**

The  $\Delta^9$  THC of the present invention is pharmaceutically pure. That is, its form is the nonionized resinous drug substance (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]-pyran-1-ol. Although its preferred embodiment in this invention is not a salt or ester, it will be readily understood by those of skill in the art that other appropriate forms of  $\Delta^9$  THC may be synthesized (e.g. esters and salts such as those described in, for example, U.S. Patent No. 5,847,128 and PCT WO 01/03690, hereby incorporated in their entirety by reference) and thus used in the practice of this invention.

**Page 20, Third Paragraph**

Male ICR mice, weighing approximately 30 g, obtained from Harlan Laboratories (Indianapolis, IN) were provided a light cycle of approximately 6 a.m. to 6 p.m., and the temperature remained approximately 23°C. The mice were placed in the lab and allowed to accommodate to the surroundings the evening prior to testing. Animals were allowed food (Harlan Teklab, Madison, WI) and water ~~ad libitum~~ ad libitum.